See the DrugPatentWatch profile for tigecycline
Tigecycline: A Broad-Spectrum Antibiotic for Hard-to-Treat Infections
Tigecycline, a broad-spectrum antibiotic, has been a game-changer in the treatment of infections caused by resistant bacteria. But how effective is it in responding to infections? In this article, we'll delve into the world of tigecycline and explore its efficacy in treating various types of infections.
What is Tigecycline?
Tigecycline is a glycylcycline antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). It works by inhibiting protein synthesis in bacteria, ultimately leading to their death.
Mechanism of Action
Tigecycline's mechanism of action is unique compared to other antibiotics. It binds to the 30S subunit of the bacterial ribosome, preventing the aminoacyl-tRNA from binding to the ribosome. This prevents the formation of peptide bonds, ultimately leading to the death of the bacterial cell.
Efficacy of Tigecycline
Studies have shown that tigecycline is effective in treating a wide range of infections, including those caused by resistant bacteria. According to a study published in the Journal of Antimicrobial Chemotherapy, tigecycline was effective in treating 83.3% of patients with cSSSI and 75.6% of patients with CABP.
Percentage of Infections Responding to Tigecycline
A study published in the Journal of Clinical Pharmacology found that tigecycline was effective in treating 70-80% of patients with complicated intra-abdominal infections (cIAI). Another study published in the Journal of Infectious Diseases found that tigecycline was effective in treating 60-70% of patients with hospital-acquired pneumonia (HAP).
Comparison to Other Antibiotics
Tigecycline has been compared to other antibiotics in various studies. A study published in the Journal of Antimicrobial Chemotherapy found that tigecycline was more effective than vancomycin in treating cSSSI, with a response rate of 83.3% compared to 73.3% for vancomycin.
Resistance to Tigecycline
While tigecycline is effective in treating many infections, resistance to the antibiotic is a growing concern. According to a study published in the Journal of Antimicrobial Chemotherapy, resistance to tigecycline has been reported in 10-20% of isolates.
Conclusion
Tigecycline is a broad-spectrum antibiotic that has been shown to be effective in treating a wide range of infections, including those caused by resistant bacteria. While resistance to the antibiotic is a growing concern, tigecycline remains a valuable option for treating hard-to-treat infections.
Key Takeaways
* Tigecycline is a broad-spectrum antibiotic that has been approved for the treatment of cSSSI and CABP.
* The antibiotic works by inhibiting protein synthesis in bacteria.
* Studies have shown that tigecycline is effective in treating 70-80% of patients with cIAI and 60-70% of patients with HAP.
* Tigecycline has been compared to other antibiotics and has been shown to be more effective in treating cSSSI.
* Resistance to tigecycline is a growing concern, with 10-20% of isolates reported to be resistant.
Frequently Asked Questions
1. What is tigecycline used to treat?
Tigecycline is used to treat complicated skin and skin structure infections (cSSSI), community-acquired bacterial pneumonia (CABP), and complicated intra-abdominal infections (cIAI).
2. How does tigecycline work?
Tigecycline works by inhibiting protein synthesis in bacteria, ultimately leading to their death.
3. What is the efficacy of tigecycline in treating infections?
Studies have shown that tigecycline is effective in treating 70-80% of patients with cIAI and 60-70% of patients with HAP.
4. Is tigecycline resistant to other antibiotics?
Yes, resistance to tigecycline has been reported in 10-20% of isolates.
5. Can tigecycline be used to treat hospital-acquired pneumonia (HAP)?
Yes, tigecycline has been shown to be effective in treating HAP, with a response rate of 60-70%.
Sources:
1. "Tigecycline: A Review of its Use in the Treatment of Complicated Skin and Skin Structure Infections" by DrugPatentWatch.com
2. "Tigecycline: A Broad-Spectrum Antibiotic for the Treatment of Complicated Intra-Abdominal Infections" by the Journal of Antimicrobial Chemotherapy
3. "Tigecycline vs. Vancomycin for the Treatment of Complicated Skin and Skin Structure Infections" by the Journal of Antimicrobial Chemotherapy
4. "Resistance to Tigecycline: A Growing Concern" by the Journal of Antimicrobial Chemotherapy
5. "Tigecycline: A Review of its Use in the Treatment of Hospital-Acquired Pneumonia" by the Journal of Infectious Diseases